中国肿瘤生物治疗杂志2024，Vol.31Issue(4)：377-382,6.DOI:10.3872/j.issn.1007-385x.2024.04.009
"宣威"多结节非小细胞肺癌驱动基因突变分析
Analysis of driver gene mutations in"Xuanwei"multi-nodular non-small cell lung cancer
摘要
Abstract
Objective:To investigate the relationship between driver gene mutations and clinicopathological features of multi-nodular non-small cell lung cancer(NSCLC),and to provide molecular diagnostic basis for the treatment of multi-nodular NSCLC patients.Methods:A total of 253 lung nodule tumor specimens from 121 patients with multiple nodules NSCLC tested at the Molecular Diagnostic Center of Yunnan Cancer Hospital between January 2018 and October 2023 were included in this study.Next-generation sequencing(NGS)or Amplification Refractory Mutation System PCR(ARMS-PCR)techniques were used to detect driver gene mutations in multi-nodular NSCLC tissues.The relationship between these mutations and clinical pathological features of patients was analyzed,in order to compare the tumor heterogeneity of lung cancer driver genes in different nodules.Results:Compared with non-"Xuanwei"NSCLC,"Xuanwei"multi-nodular NSCLC patients showed significant regional characteristics in driver gene mutations.These patients demonstrated a lower rate(20%)of epidermal growth factor receptor(EGFR)sensitive mutations(L858R,19-del),a higher rate(27.26%)of EGFR rare mutations(mainly G719/S768I,G719).The KRAS mutation rate in"Xuanwei"multi-nodular NSCLC patients(27.27%)was also significantly higher than that in non-"Xuanwei"patients(12.59%)(P<0.05).In addition,the inconsistency rate of driver gene mutations among different nodules was 69.23%in"Xuanwei"multi-nodular NSCLC patients,much higher than that in non-"Xuanwei"patients(55.07%)(P<0.05).Conclusion:"Xuanwei"multi-nodular NSCLC patients in have higher EGFR rare mutations and KRAS mutation rates,and there is higher driver gene mutation heterogeneity among different lesions in the same patient.This study will provide more options for the diagnosis and treatment strategies of"Xuanwei"multi-nodular NSCLC.关键词
非小细胞肺癌/肺结节/EGFR/KRAS/基因突变Key words
non-small cell lung cancer(NSCLC)/pulmonary nodule/epidermal growth factor receptor(EGFR)/KRAS/gene mutation分类
医药卫生引用本文复制引用
王晓雄,刘俊熙,郭银金,杜亚茜,兰云意,马露瑶,杨锐娇,吴顺先,周永春,黄云超,李权,沈正海,蔡静静,李卓颖,沈绍聪,李鸿生,刘馨,刘熙.."宣威"多结节非小细胞肺癌驱动基因突变分析[J].中国肿瘤生物治疗杂志,2024,31(4):377-382,6.基金项目
云南省教育厅科学研究基金项目(No.2023J0276) （No.2023J0276）
云南省科技厅-昆明医科大学联合专项(No.202001AY070001-150) （No.202001AY070001-150）
云南省肺癌研究重点实验室项目(No.CZ0049) （No.CZ0049）
